{"id":"NCT01189760","sponsor":"Allergan","briefTitle":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09-01","primaryCompletion":"2011-03-01","completion":"2011-09-01","firstPosted":"2010-08-27","resultsPosted":"2013-12-03","lastUpdate":"2019-04-16"},"enrollment":917,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Facial Rhytides","Crow's Feet Lines","Glabellar Lines"],"interventions":[{"type":"BIOLOGICAL","name":"onabotulinumtoxinA 24 U","otherNames":["BOTOX速","BOTOX速 Cosmetic","onabotulinumtoxinA"]},{"type":"BIOLOGICAL","name":"onabotulinumtoxinA 44 U","otherNames":["BOTOX速","BOTOX速 Cosmetic","onabotulinumtoxinA"]},{"type":"DRUG","name":"normal saline","otherNames":[]}],"arms":[{"label":"onabotulinumtoxinA 44U","type":"EXPERIMENTAL"},{"label":"onabotulinumtoxinA 24U","type":"OTHER"},{"label":"placebo (normal saline)","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)","primaryOutcome":{"measure":"Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile","timeFrame":"Baseline, Day 30","effectByArm":[{"arm":"onabotulinumtoxinA 44U","deltaMin":21.3,"sd":null},{"arm":"onabotulinumtoxinA 24U","deltaMin":20.6,"sd":null},{"arm":"Placebo (Normal Saline)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":4,"countries":["United States","Canada","France","Germany"]},"refs":{"pmids":["25485803"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":305},"commonTop":["Nasopharyngitis","Headache","Injection site haematoma"]}}